Know Cancer

or
forgot password

Allogeneic Sibling and Unrelated Donor Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Busulfan, Etoposide and Cyclophosphamide


N/A
51 Years
60 Years
Not Enrolling
Both
Acute Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Myeloproliferative Disorders, Blood and Marrow Transplant (BMT), Myelodysplastic Syndromes (MDS), Leukemia

Thank you

Trial Information

Allogeneic Sibling and Unrelated Donor Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Busulfan, Etoposide and Cyclophosphamide


To learn whether a new preparative regimen to prepare patients for bone marrow
transplantation is useful in patients above 50 years of age and whether it is useful in
patients with myelodysplastic syndromes.


Inclusion Criteria:

1) Patients aged 51-60 with acute non-lymphocytic leukemia in first or
subsequent remission and acute lymphocytic leukemia in first remission with high risk
features which include elevated white blood cell count at presentation, cytogenetic
abnormalities, extramedullary leukemia, ALL in greater than first remission and patients
with chronic myelogenous leukemia at any stage who have a histocompatible sibling donor.

2) Patients with myelodysplastic syndrome including patients with refractory anemia with
excess blasts or refractory anemia with excess blasts in transformation.

3) Patients with myeloproliferative disorders which give them poor long-term disease-free
survival, such as myeloid metaplasia or myeloid fibrosis.

4) Patients with secondary myelodysplasia following cytotoxic chemotherapy.

Exclusion Criteria:- Organ dysfunction

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

tolerability

Outcome Time Frame:

unknown

Safety Issue:

Yes

Principal Investigator

Robert S Negrin

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

BMT45

NCT ID:

NCT00186342

Start Date:

September 1992

Completion Date:

January 2009

Related Keywords:

  • Acute Disease
  • Myelodysplastic Syndromes
  • Leukemia, Myeloid, Chronic
  • Myeloproliferative Disorders
  • Blood and Marrow Transplant (BMT)
  • Myelodysplastic Syndromes (MDS)
  • Leukemia
  • Acute Disease
  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Myelodysplastic Syndromes
  • Preleukemia
  • Myeloproliferative Disorders
  • Hematologic Neoplasms

Name

Location

Stanford University School of MedicineStanford, California  94305-5317